STOKE THERAPEUTICS, INC. : conclusion of an important definitive agreement, results of operations and financial situation, disclosure of FD regulations, other events, financial statements and exhibits (form 8-K)
Article 1.01. The conclusion of an important definitive agreement.
Under the terms of the Agreement, Acadia will make an upfront payment to the Company in the amount of
With regard to each SYNGAP1 licensed product co-developed or co-marketed, the agreement will remain in force, except for early termination, until the parties have agreed to definitively abandon the development and marketing of this product under Licence. With respect to products licensed for MECP2 and the neurodevelopmental target, the agreement will remain in effect, unless terminated early, until the expiration, country by country and licensed product by licensed product, of the license term. applicable, at that time, the license for that licensed product will become fully released, royalty-free, perpetual and irrevocable in that country.
The Agreement also contains customary termination provisions by Acadia for convenience and by either party for cause, including in the event of serious breach (subject to remedy). The Company has standard reversion rights in connection with certain early termination events.
The foregoing description of the terms of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement, a copy of which will be filed with the
Article 2.02. Operating results and financial position
The audited financial statements of the Company for the year ended
The information in this Section 2.02 will not be considered “filed” for the purposes of Section 18 of the Securities Exchange Act of 1924, as amended (the “Exchange Act”), or otherwise subject to the requirements of this section, nor will it be deemed to be incorporated by reference in any other filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), except as expressly provided by specific reference in a such deposit.
Item 7.01. Regulation FD. Presentation
The Company provides the Presentation, a complete copy of which is attached hereto as Exhibit 99.1.
The information provided with this report, including Exhibits 99.1 and 99.2, will not be considered “filed” for the purposes of section 18 of the Exchange Act, or otherwise subject to the obligations of this section, nor will it be deemed to be “filed” for the purposes of section 18 of the Exchange Act. incorporated by reference in any other filing under the Exchange Act or the Securities Act, unless expressly indicated by specific reference in such filing.
Item 8.01 Other Events
The Company has also indicated that its cash, cash equivalents, marketable securities and restricted cash, including the upfront payment payable by Acadia under the agreement, are expected to fund operations through the second half of 2024.
Caution regarding forward-looking statements
This report contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: the receipt of upfront payments; receiving potential milestone payments as part of the SYNGAP1 collaboration; receipt of potential milestones and royalty payments under the MECP2 program and the third program; the ability to develop new treatments for neurodevelopmental diseases; expectations regarding the proposed transaction with Acadia; and the cash, cash equivalents, marketable securities and restricted cash expected of the Company as of
Item 9.01 Financial statements and supporting documents.
(d) Exhibits Exhibit Number Description 99.1 Presentation, dated as of
January 202299.2 Joint Press Release, dated as of January 10, 2022. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).
© Edgar online, source